

References:

1. The Internet Stroke Center. The Internet Stroke Center. An independent web resource for information about stroke care and research. <http://www.strokecenter.org/patients/about-stroke/stroke-statistics/>. Accessed April 7, 2020.
2. Stroke. Mayo Clinic. <https://www.mayoclinic.org/diseases-conditions/stroke/symptoms-causes/syc-20350113>. Published February 7, 2020. Accessed April 7, 2020.
3. Types of Stroke. Types of Stroke | Johns Hopkins Medicine. <https://www.hopkinsmedicine.org/health/conditions-and-diseases/stroke/types-of-stroke>. Accessed April 7, 2020.
4. Mi Kyoung Son N-KL, Hyung Woo Kim H-YP. Risk of ischemic stroke after atrial fibrillation diagnosis: A national sample cohort. PLOS ONE. <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0179687>. Accessed April 7, 2020.
5. Arihiro S, Todo K, Koga M, et al. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAf) study. *International Journal of Stroke*. 2016;11(5):565-574. doi:10.1177/1747493016632239
6. Diener, H.-C., Connolly, S. J., Ezekowitz, M. D., Wallentin, L., Reilly, P. A., Yang, S., ... Yusuf, S. (2010). Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. *The Lancet Neurology*, 9(12), 1157–1163. doi: 10.1016/s1474-4422(10)70274-x
7. Garcia, D. A., Wallentin, L., Lopes, R. D., Thomas, L., Alexander, J. H., Hylek, E. M., ... Granger, C. B. (2013). Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: Results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. *American Heart Journal*, 166(3), 549–558. doi: 10.1016/j.ahj.2013.05.016
8. Hong K-S, Kwon SU, Lee SH, et al. Rivaroxaban vs Warfarin Sodium in the Ultra-Early Period After Atrial Fibrillation–Related Mild Ischemic Stroke. *JAMA Neurology*. 2017;74(10):1206. doi:10.1001/jamaneurol.2017.2161
9. Kanai, Y., Oguro, H., Tahara, N., Matsuda, H., Takayoshi, H., Mitaki, S., ... Yamaguchi, S. (2018). Analysis of Recurrent Stroke Volume and Prognosis between Warfarin and Four Non–Vitamin K Antagonist Oral Anticoagulants Administration for Secondary Prevention of Stroke. *Journal of Stroke and Cerebrovascular Diseases*, 27(2), 338–345. doi: 10.1016/j.jstrokecerebrovasdis.2017.09.007

10. Rost NS, Giugliano RP, Ruff CT, et al. Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events. *Stroke*. 2016;47(8):2075-2082. doi:10.1161/strokeaha.116.013540.